Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Cavallo, Francesca ^a,b   Graziani, Grazia ^a   Antinozzi, Cristina ^a   Feldman, Darren R ^b   Houldsworth, Jane ^b   Bosl, George J ^b   Chaganti, Raju S K ^b   Moynahan, Mary Ellen ^b   Jasin, Maria ^b   Barchi, Marco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GAMMA HISTONE H2AX; GREEN FLUORESCENT PROTEIN; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; PROTEIN XPF; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GERM CELL TUMOR; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; EMBRYONAL CARCINOMA STEM CELLS; ENDONUCLEASES; ENZYME INHIBITORS; HOMOLOGOUS RECOMBINATION; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; NEOPLASM PROTEINS; NEOPLASMS, GERM CELL AND EMBRYONAL; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; TESTICULAR NEOPLASMS;

EID: 84871229659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051563     Document Type: Article

References (57)

1. Masters JR, Koberle B, (2003) Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 3: 517-525.
2. Clark AT, (2007) The stem cell identity of testicular cancer. Stem Cell Rev 3: 49-59.
3. Bosl GJ, Motzer RJ, (1997) Testicular germ-cell cancer. N Engl J Med 337: 242-253.
4. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ, (2008) Medical treatment of advanced testicular cancer. JAMA 299: 672-684.
5. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA, (1994) Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54: 362-364.
6. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW, (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83: 1002-1011.
7. Pont J, Holtl W, Kosak D, Machacek E, Kienzer H, et al. (1990) Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol 8: 16-20.
8. Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, et al. (2011) p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to Cisplatin. PLoS One 6: e19198.
9. Welsh C, Day R, McGurk C, Masters JR, Wood RD, et al. (2004) Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110: 352-361.
10. Usanova S, Piee-Staffa A, Sied U, Thomale J, Schneider A, et al. (2010) Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 9: 248.
11. Li X, Heyer WD, (2008) Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 18: 99-113.
12. Nakanishi K, Yang YG, Pierce AJ, Taniguchi T, Digweed M, et al. (2005) Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A 102: 1110-1115.
13. Bhagwat N, Olsen AL, Wang AT, Hanada K, Stuckert P, et al. (2009) XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol Cell Biol 29: 6427-6437.
14. Nakanishi K, Cavallo F, Perrouault L, Giovannangeli C, Moynahan ME, et al. (2011) Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication. Nat Struct Mol Biol 18: 500-503.
15. Raschle M, Knipscheer P, Enoiu M, Angelov T, Sun J, et al. (2008) Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 134: 969-980.
16. Akkari YM, Bateman RL, Reifsteck CA, Olson SB, Grompe M, (2000) DNA replication is required To elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol Cell Biol 20: 8283-8289.
17. Al-Minawi AZ, Lee YF, Hakansson D, Johansson F, Lundin C, et al. (2009) The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res 37: 6400-6413.
18. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66: 8109-8115.
19. Ashworth A, (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785-3790.
20. Patel AG, Sarkaria JN, Kaufmann SH, (2011) Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 108: 3406-3411.
21. Pera MF, Cooper S, Mills J, Parrington JM, (1989) Isolation and characterization of a multipotent clone of human embryonal carcinoma cells. Differentiation 42: 10-23.
22. Damjanov I, Horvat B, Gibas Z, (1993) Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Invest 68: 220-232.
23. Sperger JM, Chen X, Draper JS, Antosiewicz JE, Chon CH, et al. (2003) Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A 100: 13350-13355.
24. Andrews PW, Damjanov I, Berends J, Kumpf S, Zappavigna V, et al. (1994) Inhibition of proliferation and induction of differentiation of pluripotent human embryonal carcinoma cells by osteogenic protein-1 (or bone morphogenetic protein-7). Lab Invest 71: 243-251.
25. Josephson R, Ording CJ, Liu Y, Shin S, Lakshmipathy U, et al. (2007) Qualification of embryonal carcinoma 2102Ep as a reference for human embryonic stem cell research. Stem Cells 25: 437-446.
26. Takahashi A, Ohnishi T, (2005) Does gammaH2AX foci formation depend on the presence of DNA double strand breaks? Cancer Lett 229: 171-179.
27. Urien S, Lokiec F, (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57: 756-763.
28. Masters JR, Thomas R, Hall AG, Hogarth L, Matheson EC, et al. (1996) Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 32A: 1248-1253.
29. Jaspers NG, Raams A, Silengo MC, Wijgers N, Niedernhofer LJ, et al. (2007) First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am J Hum Genet 80: 457-466.
30. Matsumura Y, Nishigori C, Yagi T, Imamura S, Takebe H, (1998) Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms. Hum Mol Genet 7: 969-974.
31. Yagi T, Takebe H, (1983) Establishment by SV40 transformation and characteristics of a cell line of xeroderma pigmentosum belonging to complementation group F. Mutat Res. 112: 59-66.
32. Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M, (2004) Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol 24: 9305-9316.
33. Moynahan ME, Jasin M, (2010) Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 11: 196-207.
34. Pierce AJ, Johnson RD, Thompson LH, Jasin M, (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13: 2633-2638.
35. Pierce AJ, Jasin M, (2005) Measuring recombination proficiency in mouse embryonic stem cells. Methods Mol Biol 291: 373-384.
36. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, et al. (2010) PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 70: 5457-5464.
37. Di Vizio D, Cito L, Boccia A, (2005) Chieffi P, Insabato L, et al (2005) Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 24: 1882-1894.
38. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, et al. (2012) PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 18: 1015-1027.
39. Moynahan ME, Chiu JW, Koller BH, Jasin M, (1999) BRCA1 controls homology-directed DNA repair. Mol Cell 4: 511-518.
40. Bunting SF, Callen E, Kozak ML, Kim JM, Wong N, et al. (2012) BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair. Mol Cell 46: 125-135.
41. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
42. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
43. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, et al. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105: 17079-17084.
44. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244.
45. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, et al. (2010) Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 107: 2201-2206.
46. Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, et al. (2009) A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Res 11: R78.
47. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, et al. (1999) BRCA2 is required for ionizing radiation-induced assembly of RAD51 complex in vivo. Cancer Res 59: 3547-3551.
48. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, et al. (2010) Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70: 5389-5398.
49. Mangerich A, Burkle A, (2011) How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. Int J Cancer 128: 251-265.
50. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, et al. (2010) Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 9: 1775-1787.
51. Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, et al. (2002) Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 20: 1551-1561.
52. Verma R, Rigatti MJ, Belinsky GS, Godman CA, Giardina C, (2010) DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 79: 565-574.
53. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, et al. (2006) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124: 1169-1181.
54. Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S, (2011) Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis 2: e148.
55. Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, et al. (2009) Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer 101: 256-262.
56. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, et al. (2009) Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69: 6831-6838.
57. Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, et al. (2007) Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 43: 2124-2133.